Krall L P
Horm Metab Res Suppl. 1985;15:98-101.
Of all the possible atherosclerotic factors, it must be accepted that only a few can be reached by today's diabetes therapy. Control of diabetes (hopeful, but not proven); Aging--useful but only in as much as good treatment might retard the aging process (questionable); Obesity--a great generality (possibly helpful); Lipids and lipoproteins (probably helpful, although more specifics needed); Hyperinsulinism (questionable--more studies underway); Platelet changes and coagulation (probably an important area--much investigation underway); There is no real evidence that any oral hypoglycemic agent is specific for treatment in these areas. Claims are made for some of the present oral hypoglycemic agents. Are these alleged benefits due to the specific properties of these agents or are they simply reinforcement of good diabetes control? There have been some specifically favorable reports of experiments with glicazide. If these are true, this would add another important dimension to its accepted hypoglycemic role. At this time, the oral hypoglycemic agents must be considered adjuncts in good control of diabetes and as such might provide a beneficial influence on atherosclerosis and macrovascular complications, but this is hardly specific.
在所有可能的动脉粥样硬化因素中，必须承认的是，当今的糖尿病治疗只能涉及其中少数因素。糖尿病的控制（有希望，但未经证实）；衰老——有用，但仅在于良好的治疗可能会延缓衰老过程（存在疑问）；肥胖——普遍存在（可能有帮助）；脂质和脂蛋白（可能有帮助，尽管需要更多具体研究）；高胰岛素血症（存在疑问——更多研究正在进行中）；血小板变化和凝血（可能是一个重要领域——大量研究正在进行中）；没有实际证据表明任何口服降糖药在这些领域具有特异性治疗作用。目前对一些口服降糖药有相关宣称。这些所谓的益处是由于这些药物的特定特性，还是仅仅是良好糖尿病控制的强化呢？关于格列齐特的实验有一些特别有利的报告。如果这些是真的，这将为其已被认可的降糖作用增添另一个重要方面。此时，口服降糖药必须被视为良好控制糖尿病的辅助药物，因此可能对动脉粥样硬化和大血管并发症产生有益影响，但这很难说是特异性的。
